Clarity Medical Group Holding First Half 2024 Earnings: HK$0.038 loss per share (vs HK$0.015 profit in 1H 2023)

Simply Wall St

November 30, 2023

Clarity Medical Group Holding (HKG:1406) First Half 2024 Results

Key Financial Results

Revenue: HK$101.6m (down 5.6% from 1H 2023).
Net loss: HK$20.0m (down by 353% from HK$7.91m profit in 1H 2023).
HK$0.038 loss per share (down from HK$0.015 profit in 1H 2023).

earnings-and-revenue-history — SEHK:1406 Earnings and Revenue History November 30th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Clarity Medical Group Holding shares are down 7.7% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 3 warning signs with Clarity Medical Group Holding (at least 1 which makes us a bit uncomfortable), and understanding these should be part of your investment process.

If you're looking to trade Clarity Medical Group Holding, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.